Skip to main content

Research News

  • In red the part that binds to the virus, in grey the “tail” of the antibody (named Fc) that binds the receptors of the antibodies present on the different types of cells, and in yellow the LALA mutation that blocks the binding of the antibody to such receptors.

    A team of researchers from the Institute for Research in Biomedicine (IRB, USI Università della Svizzera italiana) and the Swiss biotech company Humabs BioMed SA has identified novel therapeutic monoclonal antibody candidates isolated from Zika-infected patients and new strategies for Zika virus diagnostics. An article published today in the renowned scientific journal Science describes for the first time an in-depth analysis of the human antibody and T cell immune response to the Zika virus infection with important implications for differential diagnostics and for the development of vaccines and new treatments.

  • Bacteria are rapidly developing resistance mechanisms to combat even the most effective antibiotics. Each year in the United States over 23,000 people die as a result of bacterial infections that have no treatment options, according to the Centers for Disease Control. Infections with antibiotic-resistance bacteria are extremely difficult to treat, requiring costly or toxic medications that do not always work. Scientists are constantly working to understand the mechanisms bacteria use to outsmart antibiotics and develop resistance. These mechanisms include metallo-β-lactamases (MBLs), enzymes produced by bacteria that can bind to and inactivate antibiotics. Enzymes like MBLs are one way bacteria are defying all available tools and becoming antibiotic resistant.

  • The study conducted at the UPV/EHU-University of the Basque Country describes for the first time how these receptors participate in spermatogenesisInfertility has become a major medical and social problem worldwide and many of the cases are due to male infertility. Yet the molecular mechanisms involved in spermatogenesis are only now beginning to emerge. A piece of research led by the UPV/EHU doctor Nerea Subirán has for the first time described the presence of opioids in the cells involved in the formation of spermatozoa. The work has been published in Plos One.

  •  A single dose of either of two experimental Zika vaccines fully protected mice challenged with Zika virus four or eight weeks after receiving the inoculations. The research, conducted by investigators supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, suggests that similar vaccines for people could be similarly protective.

  • High triglycerides a type of fat, or lipid, in the blood  increase the risk of heart disease and perhaps type 2 diabetes. For the first time, it has been shown that profoundly lowering triglycerides in diabetics improves their insulin sensitivity over time, which helps them maintain healthy glucose - blood sugar levels. Volanesorsen, an experimental lipid-lowering medication, improved insulin sensitivity and glucose control by significantly decreasing patients' overall hemoglobin A1c the standard clinical measurement of blood glucose levels for diabetics in a new study reported by researchers from the Perelman School of Medicine at the University of Pennsylvania. The results are published online this month in Diabetes Care.

  • A meta-analysis of studies in people with diabetes and pre-diabetes has shown that oral aloe vera use was associated with significant decreases in both fasting blood glucose (FBG) and hemoglobin A1c (HbA1c).

  • Researchers at the Universitat Autònoma de Barcelona (UAB) with the collaboration of the Institute for Bioengineering of Catalonia (IBEC), led by the professor of the UAB Department of Genetics and Microbiology Esther Julián, announced one year ago that the cells of the Mycobacterium brumae offer an improved alternative to current bladder cancer treatments such as BCG (an immunotherapy based on the Mycobacterium bovis), which can cause infections.

  •  the 94th General Session & Exhibition of the International Association for Dental Research, researcher W. Peter Holbrook, University of Iceland, will present a study titled "Development of Drugs for Local Treatment of Oral Conditions." The IADR General Session is being held in conjunction with the 3rd Meeting of the IADR Asia Pacific Region and the 35th Annual Meeting of the IADR Korean Division.

Subscribe to Research News